An observational study in Retinal Degeneration, Age-Related Macular Degeneration and Retinitis Pigmentosa, sponsored by Food and Drug Administration (FDA). Recruiting at 2 sites in United States. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2026-05-08.
Sponsored by Food and Drug Administration (FDA) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 84 studies in Retinal Degeneration with a site in United States — 11 open to participants now, 29 under way, 3 of them phase 3. Retinal Degeneration · United States.
Among the 84 studies in Retinal Degeneration with a site in United States, this one is the 10th largest by planned enrollment of the 21 observational ones that give a count, is one of 9 that started in 2021, is one of 22 observational ones, reaches primary completion later than 20 of the 26 other live ones, and was the 63rd registered.
132 studies on the registry are indexed under Retinal Degeneration; 23 are open to participants now.
Browse Retinal Degeneration studies →11 of the 84 studies in Retinal Degeneration with a site in United States are open now. Recruiting first, the newest first:
University College, London · Sites in United States, Germany, United Kingdom
Ages up to 50 · Healthy volunteers
Washington University School of Medicine · Sites in United States
Ages 50+
BlueRock Therapeutics · Sites in United States
Ages 18+
Opus Genetics, Inc · Sites in United States
Ages 4+
National Eye Institute (NEI) · Sites in United States
Ages 5–100 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 15 Retinal Degeneration studies recruiting now, 10 (67%) set no upper age limit and 3 (20%) stop at 75 or younger; 7 take children under 18; 5 take healthy volunteers.
This study: 21 Years and older · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
84 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 33 · Phase 3 13 · Phase 4 2
First in 1978; this study’s year is marked. 9 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is above the median of 78 across 32 observational studies indexed under Retinal Degeneration.
Median enrollment 51 across the 62 interventional studies, 83 across the 21 observational. Of the 50 that completed or were terminated, 27 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
58 of 84 have an industry lead sponsor. The 10 most frequent:
Food and Drug Administration (FDA) is the lead sponsor of 25 studies on the registry; 2 are open to participants now.
Of its 15 completed or terminated interventional studies of FDA-regulated products, 13 (87%) have results posted.
Food and Drug Administration (FDA) has 1 study filed under Retinal Degeneration — fewer than ten, so there is no comparison to draw.
7 of the studies in Retinal Degeneration with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04704921Phase 3AbbViePivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD | 2026-12 |
| NCT05748873SparingVisionPromising ROd-cone DYstrophy Gene therapY | 2027-02 |
| NCT06167642Johns Hopkins UniversityRetinal Atrophy and Neurofilament Light Chain in People With Multiple Sclerosis Taking Ofatumumab | 2027-03 |
| NCT06048185Nanoscope Therapeutics Inc.Non-interventional Long Term Follow-up Study of Participants Previously Enrolled in the STARLIGHT Study | 2027-05 |
| NCT04765345Jaeb Center for Health ResearchRate of Progression of PCDH15-Related Retinal Degeneration in Usher Syndrome 1F | 2027-06-30 |
Add all 7 to your calendar (.ics) → With an account.
Among the 84 studies in Retinal Degeneration with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The objective of the study is to collect adaptive optics (AO) retinal images from human subjects with outer retinal diseases (diseases of the outer retina including photoreceptor, retinal pigment epithelium (RPE), basement membrane or choroidal pathologies) to develop new diagnostic methods, biomarkers, and clinical endpoints.
Objective: The objective of the study is to collect adaptive optics (AO) retinal images from human subjects with outer retinal diseases (diseases of the outer retina including photoreceptor, retinal pigment epithelium (RPE), basement membrane or choroidal pathologies) to develop new diagnostic methods, biomarkers, and clinical endpoints.
Study Population: Up to fifty (50) healthy volunteers without eye disease (Cohort 1) and up to fifty (50) affected participants with any type of outer retinal disease (Cohort 2) will be enrolled.
Design: This is a longitudinal study protocol where participants will be imaged with investigational multimodal AO (mAO) retinal imaging systems that include optical coherence tomography (OCT) and scanning laser ophthalmoscopy (SLO) channels over three years. High resolution OCT and SLO videos will be collected while the instruments automatically detect and correct for image distortion caused by ocular aberrations. In general, videos of different retinal cellular structures will be acquired from several retinal locations using various imaging modes.
Outcome Measures: The primary outcomes for this protocol are development of new diagnostic methods and disease biomarkers, investigation of cellular morphological and functional changes due to various outer retinal diseases, and development of new AO clinical endpoints for novel therapies.
All study participants will be recruited from the NIH patient population.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects with outer retinal disease affecting the photoreceptor-retinal pigment epithelium complex will be classified by clinical exam by an experienced retina specialist. Outer retinal disease subjects will undergo adaptive optics (AO) imaging of several macular locations.
Device: Adaptive optics imaging
Age-matched healthy control subjects will undergo the same AO imaging procedures as subjects with outer retinal diseases.
Device: Adaptive optics imaging
Adaptive optics scanning laser ophthalmoscopy (AOSLO) and adaptive optics - optical coherence tomography (AO-OCT) retinal imaging
Photoreceptor (PR) density
PR density will be calculated at specific retinal eccentricities from cells counted in average AO-OCT volumes or average AOSLO frames.
Time frame: PR density will be calculated once at the AO imaging session in which PRs are the target.
Retinal pigment epithelial (RPE) cell density
RPE cell density will be calculated at specific retinal eccentricities from cells counted in average AO-OCT volumes.
Time frame: RPE cell density will be calculated once at the AO imaging session in which RPE cells are the target.
RPE cell organelle motility
RPE cell organelle motility will be calculated from the decorrelation time constant for cells segmented from a sequence of AO-OCT volumes.
Time frame: RPE motility will be calculated once at the AO imaging session in which RPE cells are the target. For the reproducibility portion of the study, RPE organelle motility will be quantified three times separated by 1-2 weeks.
PR cell function
Photoreceptor cell (cone) function will be measured from phase changes between inner segment - outer segment junction and cone outer segment tip signals in a sequence of AO-OCT volumes collected during visible light stimulation.
Time frame: PR function will be calculated once at the AO imaging session in which PR cells are stimulated. For the reproducibility portion of the study, PR cell function will be quantified three times separated by 1-2 weeks.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — De-identified AO images will be shared with external academic collaborators.
Time frame: For the duration of the study.
Access criteria: Available upon request.
Started Aug 2021 (actual). Primary completion is estimated for Sep 2028, 85 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Food and Drug Administration (FDA)